To understand mechanisms underlying MutL loss-induced endocrine treatment resistance, we analyzed previously generated reverse phase protein array (RPPA) data to compare ER+/HER2− MCF7 breast cancer cells engineered to carry shRNA against MLH1 or PMS2 against control isogenic cells with shRNA against Luciferase13. This evidence concerns the gene PMS2 and breast carcinoma.